Oxidative stress and mitochondrial dysfunction play a role in myelodysplastic syndrome development, diagnosis, and prognosis: A pilot study

Free Radical Research

Volumn 49, Issue 9, 2015, Pages 1081-1094

  Goncalves A C ^a,b   Cortesao E ^a,c   Oliveiros, B ^d   Alves, V ^a   Espadana, A I ^c   Rito, L ^a,c   Magalhaes E ^c   Lobao M J ^e   Pereira, A ^a,e   Nascimento Costa, J M ^a,c   Mota Vieira, L ^f,g,h   Sarmento Ribeiro, A B ^a,b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^d UNIVERSITY OF COIMBRA   (Portugal)

^e Hospital Distrital da Figueira da Foz   (Portugal)

^f Hospital of Divino Espirito Santo of Ponta Delgada   (Portugal)

^g INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^h UNIVERSITY OF LISBON   (Portugal)

Author keywords

Biomarkers; Mitochondrial membrane potential; Reactive oxygen species; Reduced glutathione; Superoxide peroxides ratio

Indexed keywords

DICHLORODIHYDROFLUORESCEIN DIACETATE; FERRITIN; GLUTATHIONE; PEROXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; ANTIOXIDANT; BIOLOGICAL MARKER;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ERYTHROID PRECURSOR CELL; FEMALE; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; LOW RISK PATIENT; LYMPHOCYTE; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; MYELODYSPLASTIC SYNDROME; OXIDATIVE STRESS; PATHOGENESIS; PILOT STUDY; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; ROLE PLAYING; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; BLOOD; CASE CONTROL STUDY; CELL SEPARATION; CHEMISTRY; CYTOLOGY; METABOLISM; MITOCHONDRION; MYELODYSPLASTIC SYNDROMES; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; APOPTOSIS; BIOMARKERS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELL SEPARATION; FEMALE; FERRITINS; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIA; MYELODYSPLASTIC SYNDROMES; OXIDATIVE STRESS; PILOT PROJECTS; PROGNOSIS; REACTIVE OXYGEN SPECIES;

EID: 84938601886     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2015.1035268     Document Type: Article

References (45)

1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111: 4841-4851.
2. Platzbecker U, Meredyth-Stewart M, Ehninger G. The pathogenesis of myelodysplastic syndromes (MDS) . Cancer Treat Res 2007;33:S53-S58.
3. Teferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
4. Shih AH, Levine RL. Molecular biology of myelodysplastic syndromes. Semin Oncol 2011;38:613-620.
5. Greenberg PL. The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features. J Natl Compr Canc Netw 2013;11:877-884.
6. Adès L, Itzykson, R, Fenaux P. Myelodysplastic syndromes. Lancet 2014;383:2239-2252.
7. Invernizzi R. Iron overload, oxidative damage and ineff ective erythropoiesis in myelodysplastic syndromes . European Hae-matology 2010;4:34-38.
8. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease . Int J Biochem Cell Biol 2007;39:44-84.
9. Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? Blood 2011 ; 117 : 5816-5826.
10. Farquhar MJ, Bowen DT. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003;77:342-350.
11. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells . Antioxid Redox Signal 2012 ; 16 : 1215-1228.
12. Ghaff ari S . Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal 2008;10: 1923-1940.
13. Antico Arciuch VG, Elguero ME, Poderoso JJ, Carreras MC Mitochondrial regulation of cell cycle and proliferation . Antioxid Redox Signal 2012;16:1150-1180.
14. Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007;83: 84-92.
15. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME . Oxidative stress and cancer: an overview . Ageing Res Rev 2013;12:376-390.
16. Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL, et al. Nontransferrinbound iron in myelodysplastic syndromes: a marker of ineff ective erythropoiesis? Hematol J 2000;1:153-158.
17. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34 + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factoralpha concentration . Br J Haematol 1997;99:625-631.
18. Novotna B, Bagryantseva Y, Siskova M, Neuwirtova R. Oxidative DNA damage in bone marrow cells of patients with lowrisk myelodysplastic syndrome. Leuk Res 2009;33: 340-343.
19. Honda M, Yamada Y, Tomonaga M, Ichinose H, Kamihira S. Correlation of urinary 8hydroxy2 ′ deoxyguanosine (8OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study . Leuk Res 2000 ; 24 : 461-468.
20. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome . Eur J Haematol 2007;79:463-467.
21. Brunning R, Orazi A, Germing U, Le Beau MM. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds.). WHO classifi cation of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. pp. 88-103.
22. Yuan CM, Douglas-Nikitin VK, Ahrens KP, Luchetta GR, Braylan RC, Yang L. DRAQ5-based DNA content analysis of hematolymphoid cell subpopulations discriminated by surface antigens and light scatter properties . Cytometry B Clin Cytom 2004;58:47-52.
23. Caldwell CW, Patterson WP, Toalson BD, Yesus YW. Surface and cytoplasmic expression of CD45 antigen isoforms in normal and malignant myeloid cell diff erentiation . Am J Clin Pathol 1991;95:180-187.
24. Almeida S, Sarmento-Ribeiro AB, Januário C, Rego AC, Oliveira CR . Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington ' s disease patients. Biochem Biophys Res Commun 2008;374:599-603.
25. Zielonka J, Vasquez-Vivar J, Kalyanaraman B. Detection of 2-hydroxyethidium in cellular systems: a unique marker product of superoxide and hydroethidine . Nat Protoc 2008 ; 3 : 8-21.
26. O'Connor JE, Kimler BF, Morgan MC, Tempas KJ. A fl ow cytometric assay for intracellular nonprotein thiols using mercury orange. Cytometry 1988;9:529-532.
27. Voukelatou G, Thanopoulou E, Dallas K, Fertakis V, Dimopou-lou A, Micheva I, et al. CD34 + marrow cells from MDS patients are characterized by higher levels of intracellular reactive oxygen species and inadequate antioxidant defences . Leuk Res 2009;33:S93-S94
28. Ghoti H, Fibach E, Merkel D, Perez-Avraham G, Grisariu S, Rachmilewitz EA . Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes . Haematologica 2010;95:1433-1434.
29. Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, et al. Oxidative stress levels in myelodysplastic syndrome patients: their relationship to serum ferritin and haemoglobin values. J IntMed Res 2011;39:1941-1945.
30. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis . Free Radic Biol Med 2010 ; 48 : 749-762.
31. Cortesão EC, Gonçalves AC, Sousa MI, Moucho C, Rito L, Magalhães E, et al. Evaluation of Apoptotric Markers in Mye-lodysplasic Syndrome Patients . Blood (ASH Annual Meeting Abstracts) 2008;112:5094.
32. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A . The role of apoptosis, proliferation, and the BCL-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96: 3932-3938.
33. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes . Int J Hematol 2001 ; 73 : 416-428.
34. Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu RV, Maciejewski JP . Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome . Leukemia 2008;22:551-558.
35. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis . Mutat Res 2010 ; 704 : 152-159.
36. Pervaiz S, Clement MV. Superoxide anion: oncogenic reactive oxygen species? Int J Biochem Cell Biol 2007 ; 39 : 1297-1304.
37. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxi-dative stress: implications for cell death . Annu Rev Pharmacol Toxicol 2007;47:143-183.
38. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports RASdependent oncogenic transformation. Science 2009;324:1713-1716.
39. Kang J, Pervaiz S. Mitochondria: redox metabolism and dysfunction. Biochem Res Int 2012;2012:896751.
40. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes . Hematology Am Soc Hematol Educ Program 2002;136-161.
41. Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E. Mitochondria in hematopoiesis and hematological diseases . Oncogene 2006;25:4757-4767.
42. Wulfert M, Küpper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes . Exp Hematol 2008 ; 36:577-586.
43. Schildgen V, Wulfert M, Gattermann N. Impaired mitochon-drial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasiarelated changes . Exp Hematol 2011;39:666-675.e1.
44. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009;23:S15-S9.
45. Ribas V, García-Ruiz C, Fernández-Checa JC. Glutathione and mitochondria. Front Pharmacol 2014;5:151.